US 12,290,511 B2
Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Hisashi Kawata, Osaka (JP); Noriko Kawabata, Osaka (JP); and Naveed Shams, Emeryville, CA (US)
Assigned to SANTEN PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed by Santen Pharmaceutical Co., Ltd., Osaka (JP)
Filed on May 10, 2023, as Appl. No. 18/314,909.
Application 18/314,909 is a continuation of application No. 16/957,749, granted, now 11,666,563, previously published as PCT/JP2018/048228, filed on Dec. 27, 2018.
Claims priority of provisional application 62/611,017, filed on Dec. 28, 2017.
Prior Publication US 2023/0277515 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/444 (2006.01); A61K 9/00 (2006.01); A61K 31/5575 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 9/0048 (2013.01); A61K 31/5575 (2013.01)] 10 Claims
 
1. A method of treating glaucoma or ocular hypertension, comprising: administering to a patient a pharmaceutical preparation containing omidenepag, an ester thereof, or a salt thereof as an active ingredient, wherein the patient is a patient with inadequate efficacies of latanoprost such that, when subjected to treatment with latanoprost, a) a width of decrease between pre-treatment intraocular pressure and post-treatment intraocular pressure is 4.5 mmHg or less, or b) a rate of decrease between pre-treatment intraocular pressure and post-treatment intraocular pressure is 18% or less.